Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease

Lei Wang, Jun Yang, Lei Guo, Dale Uyeminami, Hua Dong, Bruce D. Hammock, Kent E Pinkerton

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Tobacco smoke-induced chronic obstructive pulmonary disease (COPD) is a prolonged inflammatory condition of the lungs characterized by progressive and largely irreversible airflow limitation attributable to a number of pathologic mechanisms, including bronchitis, bronchiolitis, emphysema, mucus plugging, pulmonary hypertension, and small-airway obstruction. Soluble epoxide hydrolase inhibitors (sEHIs) demonstrated anti-inflammatory properties in a rat model after acute exposure to tobacco smoke. We compared the efficacy of sEHI t-TUCB (trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]- cyclohexyloxy}-benzoic acid) and the phosphodiesterase-4 (PDE4) inhibitor Rolipram (Biomol International, Enzo Life Sciences, Farmingdale, NY) to reduce lung injury and inflammation after subacute exposure to tobacco smoke over a period of 4 weeks. Pulmonary physiology, bronchoalveolar lavage, cytokine production, and histopathology were analyzed to determine the efficacy of sEHI and Rolipramto ameliorate tobacco smoke - induced inflammation andinjury in the spontaneously hypertensive rat. Both t-TUCB and Rolipram inhibited neutrophil elevation in bronchoalveolar lavage. sEHI t-TUCB suppressed IFN-γ, while improving lung function by reducing tobacco smoke - induced total respiratory resistance and tissue damping (small-airway and peripheral tissue resistance). Increases in tobacco smoke - induced alveolar airspace size were attenuated by t-TUCB. Rolipram inhibited the production of airway mucus. Both t-TUCB and Rolipram inhibited vascular remodeling - related growth factor. These findings suggest that sEHI t-TUCB has therapeutic potential for treating COPD by improving lung function and attenuating the lung inflammation and emphysematous changes caused by tobacco smoke. To the best of our knowledge, this is the first report to demonstrate that sEHI exerts significant protective effects after repeated, subacute tobacco smoke - induced lung injury in a rat model of COPD.

Original languageEnglish (US)
Pages (from-to)614-622
Number of pages9
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume46
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Epoxide Hydrolases
Pulmonary diseases
Tobacco
Smoke
Chronic Obstructive Pulmonary Disease
Rolipram
Rats
Lung
Lung Injury
Bronchoalveolar Lavage
Mucus
Pneumonia
Phosphodiesterase 4 Inhibitors
Tissue
Bronchiolitis
Biological Science Disciplines
Bronchitis
Physiology
Emphysema
Inbred SHR Rats

Keywords

  • Airway obstruction
  • Anti-inflammatory agents
  • Experimental animal models

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. / Wang, Lei; Yang, Jun; Guo, Lei; Uyeminami, Dale; Dong, Hua; Hammock, Bruce D.; Pinkerton, Kent E.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 46, No. 5, 05.2012, p. 614-622.

Research output: Contribution to journalArticle

Wang, Lei ; Yang, Jun ; Guo, Lei ; Uyeminami, Dale ; Dong, Hua ; Hammock, Bruce D. ; Pinkerton, Kent E. / Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease. In: American Journal of Respiratory Cell and Molecular Biology. 2012 ; Vol. 46, No. 5. pp. 614-622.
@article{3356e3b37fe74b84a8a34f09394744f8,
title = "Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease",
abstract = "Tobacco smoke-induced chronic obstructive pulmonary disease (COPD) is a prolonged inflammatory condition of the lungs characterized by progressive and largely irreversible airflow limitation attributable to a number of pathologic mechanisms, including bronchitis, bronchiolitis, emphysema, mucus plugging, pulmonary hypertension, and small-airway obstruction. Soluble epoxide hydrolase inhibitors (sEHIs) demonstrated anti-inflammatory properties in a rat model after acute exposure to tobacco smoke. We compared the efficacy of sEHI t-TUCB (trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]- cyclohexyloxy}-benzoic acid) and the phosphodiesterase-4 (PDE4) inhibitor Rolipram (Biomol International, Enzo Life Sciences, Farmingdale, NY) to reduce lung injury and inflammation after subacute exposure to tobacco smoke over a period of 4 weeks. Pulmonary physiology, bronchoalveolar lavage, cytokine production, and histopathology were analyzed to determine the efficacy of sEHI and Rolipramto ameliorate tobacco smoke - induced inflammation andinjury in the spontaneously hypertensive rat. Both t-TUCB and Rolipram inhibited neutrophil elevation in bronchoalveolar lavage. sEHI t-TUCB suppressed IFN-γ, while improving lung function by reducing tobacco smoke - induced total respiratory resistance and tissue damping (small-airway and peripheral tissue resistance). Increases in tobacco smoke - induced alveolar airspace size were attenuated by t-TUCB. Rolipram inhibited the production of airway mucus. Both t-TUCB and Rolipram inhibited vascular remodeling - related growth factor. These findings suggest that sEHI t-TUCB has therapeutic potential for treating COPD by improving lung function and attenuating the lung inflammation and emphysematous changes caused by tobacco smoke. To the best of our knowledge, this is the first report to demonstrate that sEHI exerts significant protective effects after repeated, subacute tobacco smoke - induced lung injury in a rat model of COPD.",
keywords = "Airway obstruction, Anti-inflammatory agents, Experimental animal models",
author = "Lei Wang and Jun Yang and Lei Guo and Dale Uyeminami and Hua Dong and Hammock, {Bruce D.} and Pinkerton, {Kent E}",
year = "2012",
month = "5",
doi = "10.1165/rcmb.2011-0359OC",
language = "English (US)",
volume = "46",
pages = "614--622",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "5",

}

TY - JOUR

T1 - Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease

AU - Wang, Lei

AU - Yang, Jun

AU - Guo, Lei

AU - Uyeminami, Dale

AU - Dong, Hua

AU - Hammock, Bruce D.

AU - Pinkerton, Kent E

PY - 2012/5

Y1 - 2012/5

N2 - Tobacco smoke-induced chronic obstructive pulmonary disease (COPD) is a prolonged inflammatory condition of the lungs characterized by progressive and largely irreversible airflow limitation attributable to a number of pathologic mechanisms, including bronchitis, bronchiolitis, emphysema, mucus plugging, pulmonary hypertension, and small-airway obstruction. Soluble epoxide hydrolase inhibitors (sEHIs) demonstrated anti-inflammatory properties in a rat model after acute exposure to tobacco smoke. We compared the efficacy of sEHI t-TUCB (trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]- cyclohexyloxy}-benzoic acid) and the phosphodiesterase-4 (PDE4) inhibitor Rolipram (Biomol International, Enzo Life Sciences, Farmingdale, NY) to reduce lung injury and inflammation after subacute exposure to tobacco smoke over a period of 4 weeks. Pulmonary physiology, bronchoalveolar lavage, cytokine production, and histopathology were analyzed to determine the efficacy of sEHI and Rolipramto ameliorate tobacco smoke - induced inflammation andinjury in the spontaneously hypertensive rat. Both t-TUCB and Rolipram inhibited neutrophil elevation in bronchoalveolar lavage. sEHI t-TUCB suppressed IFN-γ, while improving lung function by reducing tobacco smoke - induced total respiratory resistance and tissue damping (small-airway and peripheral tissue resistance). Increases in tobacco smoke - induced alveolar airspace size were attenuated by t-TUCB. Rolipram inhibited the production of airway mucus. Both t-TUCB and Rolipram inhibited vascular remodeling - related growth factor. These findings suggest that sEHI t-TUCB has therapeutic potential for treating COPD by improving lung function and attenuating the lung inflammation and emphysematous changes caused by tobacco smoke. To the best of our knowledge, this is the first report to demonstrate that sEHI exerts significant protective effects after repeated, subacute tobacco smoke - induced lung injury in a rat model of COPD.

AB - Tobacco smoke-induced chronic obstructive pulmonary disease (COPD) is a prolonged inflammatory condition of the lungs characterized by progressive and largely irreversible airflow limitation attributable to a number of pathologic mechanisms, including bronchitis, bronchiolitis, emphysema, mucus plugging, pulmonary hypertension, and small-airway obstruction. Soluble epoxide hydrolase inhibitors (sEHIs) demonstrated anti-inflammatory properties in a rat model after acute exposure to tobacco smoke. We compared the efficacy of sEHI t-TUCB (trans-4-{4-[3-(4-trifluoromethoxy-phenyl)-ureido]- cyclohexyloxy}-benzoic acid) and the phosphodiesterase-4 (PDE4) inhibitor Rolipram (Biomol International, Enzo Life Sciences, Farmingdale, NY) to reduce lung injury and inflammation after subacute exposure to tobacco smoke over a period of 4 weeks. Pulmonary physiology, bronchoalveolar lavage, cytokine production, and histopathology were analyzed to determine the efficacy of sEHI and Rolipramto ameliorate tobacco smoke - induced inflammation andinjury in the spontaneously hypertensive rat. Both t-TUCB and Rolipram inhibited neutrophil elevation in bronchoalveolar lavage. sEHI t-TUCB suppressed IFN-γ, while improving lung function by reducing tobacco smoke - induced total respiratory resistance and tissue damping (small-airway and peripheral tissue resistance). Increases in tobacco smoke - induced alveolar airspace size were attenuated by t-TUCB. Rolipram inhibited the production of airway mucus. Both t-TUCB and Rolipram inhibited vascular remodeling - related growth factor. These findings suggest that sEHI t-TUCB has therapeutic potential for treating COPD by improving lung function and attenuating the lung inflammation and emphysematous changes caused by tobacco smoke. To the best of our knowledge, this is the first report to demonstrate that sEHI exerts significant protective effects after repeated, subacute tobacco smoke - induced lung injury in a rat model of COPD.

KW - Airway obstruction

KW - Anti-inflammatory agents

KW - Experimental animal models

UR - http://www.scopus.com/inward/record.url?scp=84860511513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860511513&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2011-0359OC

DO - 10.1165/rcmb.2011-0359OC

M3 - Article

C2 - 22180869

AN - SCOPUS:84860511513

VL - 46

SP - 614

EP - 622

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 5

ER -